Valuation: Genmab A/S

Capitalization 110B 17.25B 14.7B 13.6B 12.81B 23.86B 1,605B 24.35B 160B 62.44B 771B 64.75B 63.38B 2,746B P/E ratio 2026 *
23.1x
P/E ratio 2027 * 15.7x
Enterprise value 111B 17.46B 14.87B 13.76B 12.96B 24.14B 1,623B 24.63B 161B 63.17B 780B 65.51B 64.12B 2,778B EV / Sales 2026 *
4.04x
EV / Sales 2027 * 3.35x
Free-Float
95.94%
Yield 2026 *
-
Yield 2027 * -
1 day-0.69%
1 week+1.79%
Current month+4.50%
1 month+0.03%
3 months-17.97%
6 months-12.43%
Current year-11.69%
1 week 1,728.5
Extreme 1728.5
1,828.5
1 month 1,582
Extreme 1582
1,828.5
Current year 1,582
Extreme 1582
2,257
1 year 1,204.5
Extreme 1204.5
2,257
3 years 1,157
Extreme 1157
2,947
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 31/05/2010
Director of Finance/CFO 48 29/02/2020
Chief Tech/Sci/R&D Officer - 15/08/2024
Director TitleAgeSince
Director/Board Member 75 31/10/2003
Director/Board Member 58 31/12/2014
Director/Board Member 75 31/12/2014
Change 5d. change 1-year change 3-years change Capi.($)
-0.69%+1.79%+47.08%-31.73% 17.32B
+0.80%+5.38%+39.70%+94.08% 49.22B
+0.13%+6.34%+103.31%+25.67% 46.83B
-3.00%-4.69%+138.87%+822.04% 34.45B
+3.83%+4.74%+2.56%-25.22% 23.26B
+1.01%+2.63%+86.78%-24.18% 18.77B
+1.99%-1.64%+86.38%+213.73% 15.93B
+1.86%+1.50%-2.38%+1,185.62% 14.97B
+1.61%-2.09%+75.57% - 14.44B
-0.89%-4.99%+69.06%+111.80% 12.03B
Average +0.67%+0.03%+64.69%+263.53% 24.72B
Weighted average by Cap. +0.45%+1.33%+70.15%+236.54%

Financials

2026 *2027 *
Net sales 27.53B 4.32B 3.68B 3.41B 3.21B 5.98B 402B 6.1B 39.98B 15.64B 193B 16.22B 15.88B 688B 32.67B 5.13B 4.37B 4.04B 3.81B 7.09B 477B 7.24B 47.44B 18.56B 229B 19.25B 18.84B 816B
Net income 4.86B 764M 651M 602M 567M 1.06B 71.04B 1.08B 7.06B 2.76B 34.11B 2.87B 2.81B 122B 7.5B 1.18B 1B 928M 874M 1.63B 109B 1.66B 10.89B 4.26B 52.58B 4.42B 4.32B 187B
Net Debt 1.29B 202M 172M 159M 150M 279M 18.78B 285M 1.87B 731M 9.02B 758M 742M 32.13B -421M -66.16M -56.36M -52.16M -49.11M -91.48M -6.15B -93.35M -612M -239M -2.95B -248M -243M -10.53B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
2,973
Date Price Change Volume
10/04/26 1,790.00 kr -0.69% 100,146
09/04/26 1,802.50 kr +0.78% 145,523
08/04/26 1,788.50 kr +2.11% 173,107
07/04/26 1,751.50 kr -0.40% 148,296
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,790.00DKK
Average target price
2,232.52DKK
Spread / Average Target
+24.72%

Quarterly revenue - Rate of surprise